AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15782519 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Schirmer test (MST)
Number of subjects: 61
Study 15782519 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adult volunteers)
Number of subjects: 61
Study 12538185 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sevoflurane with large N(2)O concentration
Number of subjects: 18
Study 12538185 — intervention group
Group type: COMPARATOR
Intervention: 6% sevoflurane with small N(2)O concentration
Number of subjects: 18
Study 12538185 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O
Number of subjects: 18
Study 12538185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 18
Study 10807486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 220
Study 10807486 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 220
Study 8971298 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight of midazolam
Number of subjects: 40
Study 8971298 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 40
Study 1611111 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Number of subjects: 87
Study 1611111 — intervention group
Group type: COMPARATOR
Intervention: 10 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Number of subjects: 87
Study 1611111 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group (10 MU)
Number of subjects: 87
Study 1611111 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (100 MU)
Number of subjects: 87
Study 6704008 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.25% betaxolol
Number of subjects: 10
Study 6704008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31653510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-KLH conjugate + OPT-821
Number of subjects: 171
Study 31653510 — intervention group
Group type: COMPARATOR
Intervention: OPT-821
Number of subjects: 171
Study 29449096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Conversation Maps (CMs)
Number of subjects: 21
Study 29449096 — intervention group
Group type: COMPARATOR
Intervention: Traditional Group Education (TE)
Number of subjects: 21
Study 27050630 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TDF+LPV/r
Number of subjects: 30
Study 27050630 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Number of subjects: 30
Study 27050630 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TDF+DRV/r
Number of subjects: 30
Study 25108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 mcg
Number of subjects: 248
Study 25108545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 21535998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (SR) for 12 weeks
Number of subjects: 32
Study 21535998 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 32
Study 19948566 — intervention group
Group type: EXPERIMENTAL
Intervention: Management model proposed by the ESC
Number of subjects: 941
Study 17622274 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 12
Study 17622274 — intervention group
Group type: COMPARATOR
Intervention: Ferric gluconate
Number of subjects: 12
Study 16234333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 h infusion of 0.5 g every 6 h
Number of subjects: 8
Study 16234333 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h infusion of 0.5 g every 6 h
Number of subjects: 8
Study 16234333 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h infusion of 1 g every 6 h
Number of subjects: 8
Study 11834876 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg over 10 min)
Number of subjects: 5
Study 11834876 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion (0.1 microg/kg/min over 60 min)
Number of subjects: 5
Study 10023946 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide application in sprayed villages (Group A)
Number of subjects: 0
Study 10023946 — intervention group
Group type: COMPARATOR
Intervention: Unsprayed villages (Control)
Number of subjects: 0
Study 10023946 — intervention group
Group type: EXPERIMENTAL
Intervention: Baited fly traps in Group A villages (1997)
Number of subjects: 0
Study 7771621 — intervention group
Group type: COMPARATOR
Intervention: Controlled pancreaticocutaneous fistula (CPF)
Number of subjects: 35
Study 7771621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 35
Study 3605131 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra snack at bedtime if capillary blood glucose levels at 10:30 P.M. were 120 mg/dl or less
Number of subjects: 20
Study 3605131 — intervention group
Group type: COMPARATOR
Intervention: Usual routine of one evening snack at 9 P.M.
Number of subjects: 20
Study 3605131 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood glucose concentration at 10:30 P.M.
Number of subjects: 20
Study 30005634 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal steep‐axis incision (group A2)
Number of subjects: 77
Study 30005634 — intervention group
Group type: COMPARATOR
Intervention: 135° incision (group B2)
Number of subjects: 77
Study 26459247 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-minute fast
Number of subjects: 24
Study 26459247 — intervention group
Group type: COMPARATOR
Intervention: 6-hour fast (control)
Number of subjects: 24
Study 24114251 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) application over the wound during total knee arthroplasty (TKA)
Number of subjects: 40
Study 24114251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP application)
Number of subjects: 40
Study 24377675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 64
Study 24377675 — intervention group
Group type: COMPARATOR
Intervention: Propofol TCI sedation
Number of subjects: 64
Study 20572368 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol (50 mg/day) and medroxy progesterone acetate (2.5 mg/day) for 3 months
Number of subjects: 42
Study 20572368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (both transdermal and oral)
Number of subjects: 42
Study 18323719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program (5 monthly sessions)
Number of subjects: 64
Study 18323719 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient follow-ups (control)
Number of subjects: 64
Study 19654220 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting intervention
Number of subjects: 664
Study 15569875 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 46
Study 15569875 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 46
Study 15569875 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation alone (control)
Number of subjects: 46
Study 11573524 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 25
Study 11573524 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 25
Study 11573524 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 25
Study 11573524 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 25
Study 11573524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 25
Study 9388801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity counseling
Number of subjects: 235
Study 9388801 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise program
Number of subjects: 235
Study 7695927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia with potassium (CBC)
Number of subjects: 40
Study 7695927 — intervention group
Group type: COMPARATOR
Intervention: Cold blood only
Number of subjects: 40
Study 3098401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutter factor VIII
Number of subjects: 49
Study 3098401 — intervention group
Group type: COMPARATOR
Intervention: Connaught factor VIII
Number of subjects: 49
Study 11290878 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 2,000 mg
Number of subjects: 0
Study 11290878 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 mg
Number of subjects: 0
Study 11290878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31326059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish and 1450-ppm fluoride toothpaste
Number of subjects: 0
Study 30136291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral taurine supplementation (2 g/day)
Number of subjects: 49
Study 30136291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 27428211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings containing 25 mg dapivirine (DPV)/100 mg maraviroc (MVC)
Number of subjects: 48
Study 27428211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings containing DPV only
Number of subjects: 48
Study 27428211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings containing MVC only
Number of subjects: 48
Study 27428211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25456370 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m² per day, adjusted for tolerability to attain blood trough concentrations of 5-15 ng/mL)
Number of subjects: 111
Study 25456370 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 111
Study 22592573 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron in saline
Number of subjects: 135
Study 22592573 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol in saline
Number of subjects: 135
Study 22592573 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 135
Study 20196917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22
Study 20196917 — intervention group
Group type: COMPARATOR
Intervention: Trp-balanced placebo (Pla)
Number of subjects: 22
Study 17914514 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 205
Study 17914514 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheostomy (ST)
Number of subjects: 205
Study 17914514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ST and PDT)
Number of subjects: 205
Study 15678233 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory biofeedback alone (group 1)
Number of subjects: 36
Study 15678233 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory plus home biofeedback (group 2)
Number of subjects: 36
Study 15678233 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Laboratory biofeedback alone and Laboratory plus home biofeedback)
Number of subjects: 36
Study 12217282 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 67
Study 12217282 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 67
Study 9436865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 14
Study 9436865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (Ethanol + Nifedipine)
Number of subjects: 14
Study 9436865 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 7787469 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 7787469 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2652029 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 0
Study 2652029 — intervention group
Group type: COMPARATOR
Intervention: Long‐acting gas
Number of subjects: 0
Study 1204278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg
Number of subjects: 0
Study 1204278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 2.5 mg
Number of subjects: 0
Study 1204278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 5 mg
Number of subjects: 0
Study 1204278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg or 2 mg two times daily
Number of subjects: 0
Study 1204278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 5 mg after 7-day drug period
Number of subjects: 0
Study 31916452 — intervention group
Group type: EXPERIMENTAL
Intervention: Early activity postinjury with a home exercise program involving progressive loading exercises after cast removal
Number of subjects: 129
Study 31948903 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg plus placebo every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Number of subjects: 600
Study 31948903 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Number of subjects: 600
Study 31948903 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo every 4 weeks for 4 cycles, followed by single placebo every 4 weeks
Number of subjects: 600
Study 31948903 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival rates, objective response rate, and safety and tolerability
Number of subjects: 600
Study 31058448 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid injection (100 mL/5 mg) after operation, along with oral calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Number of subjects: 482
Study 31058448 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Number of subjects: 482
Study 28845470 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (educational webinar for dialysis medical directors, educational video for patients, educational video for dialysis staff, dialysis-facility specific transplant performance feedback report)
Number of subjects: 600
Study 28845470 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 600
Study 25586811 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth services (health monitoring and patient safety)
Number of subjects: 859
Study 25586811 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 859
Study 23444004 — intervention group
Group type: EXPERIMENTAL
Intervention: RULER Approach to Social and Emotional Learning
Number of subjects: 62
Study 23444004 — intervention group
Group type: COMPARATOR
Intervention: Standard ELA curriculum
Number of subjects: 62
Study 21584942 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 1 mg twice a day
Number of subjects: 140
Study 21584942 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 3 mg twice a day
Number of subjects: 140
Study 21584942 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice a day
Number of subjects: 140
Study 21584942 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice a day
Number of subjects: 140
Study 21584942 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study 19673652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza vaccine (CCIV)
Number of subjects: 613
Study 19673652 — intervention group
Group type: COMPARATOR
Intervention: Egg-based trivalent inactivated influenza vaccine (TIV)
Number of subjects: 613
Study 16328852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiger II catheter (5F)
Number of subjects: 160
Study 16328852 — intervention group
Group type: COMPARATOR
Intervention: Judkins catheter (5F R4, L4)
Number of subjects: 160
Study 12833014 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 90
Study 12833014 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 90
Study 12833014 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 90
Study 10827213 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit and vegetable diet (500g daily)
Number of subjects: 47
Study 10827213 — intervention group
Group type: COMPARATOR
Intervention: Low fruit and vegetable diet (100g daily)
Number of subjects: 47
Study 8893577 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-labeled monoclonal granulocyte antibody scintigraphy
Number of subjects: 29
Study 8893577 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-labeled monoclonal granulocyte antibody scintigraphy combined with tomographic scan
Number of subjects: 29
Study 1671468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide and oral prednisone (n = 55)
Number of subjects: 168
Study 1671468 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral cyclophosphamide, alternate day prednisone (22 weeks), and weekly plasma exchange (20 weeks) (n = 57)
Number of subjects: 168
Study 1671468 — intervention group
Group type: COMPARATOR
Intervention: Placebo medications and sham plasma exchange (n = 56)
Number of subjects: 168
Study 6839914 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid regimen (172 +/- 25 ml/kg/day)
Number of subjects: 73
Study 6839914 — intervention group
Group type: COMPARATOR
Intervention: Low fluid regimen (121 +/- 13 ml/kg/day)
Number of subjects: 73
Study 31533539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA + rilpivirine LA once every 4 weeks
Number of subjects: 286
Study 31533539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA + rilpivirine LA once every 8 weeks
Number of subjects: 286
Study 31533539 — intervention group
Group type: COMPARATOR
Intervention: Oral maintenance group
Number of subjects: 286
Study 31533539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA + rilpivirine LA (both 4-week and 8-week groups)
Number of subjects: 286
Study 29222227 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-guided intervention (n=30) with Blue-toothed UA-767Plus BT BP device and smartphone for monitoring BP for 3 months
Number of subjects: 60
Study 29222227 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (n=30)
Number of subjects: 60
Study 29222227 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-guided intervention (n=30)
Number of subjects: 60
Study 27487543 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable orthodontic appliances of own design and additional application of own theoretical and practical developments (Group 1)
Number of subjects: 37
Study 27487543 — intervention group
Group type: COMPARATOR
Intervention: Traditional removable appliances with screws (Group 2)
Number of subjects: 37
Study 24977716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (80-100 mg/d)
Number of subjects: 524
Study 24977716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 22067667 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine
Number of subjects: 1368
Study 22067667 — intervention group
Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 1368
Study 19010983 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 66
Study 19010983 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 66
Study 19010983 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study 17985809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy (MABT)
Number of subjects: 14
Study 17985809 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 14
Study 15764277 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid (betamethasone), applied twice daily for 4 weeks
Number of subjects: 137
Study 15764277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 15764277 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid (betamethasone) after 4 weeks for non-responders
Number of subjects: 137
Study 15764277 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 18 months
Number of subjects: 137
Study 12475833 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP, 80 micro g/d
Number of subjects: 353
Study 12475833 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP, 160 micro g/d
Number of subjects: 353
Study 12475833 — intervention group
Group type: COMPARATOR
Intervention: HFA‐placebo
Number of subjects: 353
Study 10101704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-cleaning technique using a toothbrush without paste (dry brushing)
Number of subjects: 74
Study 10101704 — intervention group
Group type: COMPARATOR
Intervention: Tooth-cleaning technique using a brush attached to a rotary instrument with fluoridated prophy paste
Number of subjects: 74
Study 7921214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (SB-75) 300 micrograms sc
Number of subjects: 0
Study 7921214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (SB-75) 75, 150, 300, 600, and 1200 micrograms (im, sc, iv)
Number of subjects: 0
Study 3401697 — intervention group
Group type: EXPERIMENTAL
Intervention: DS (word recognition and decoding skills training)
Number of subjects: 0
Study 3401697 — intervention group
Group type: EXPERIMENTAL
Intervention: OWLS (oral and written language training)
Number of subjects: 0
Study 3401697 — intervention group
Group type: COMPARATOR
Intervention: Classroom survival skills (alternative treatment control)
Number of subjects: 0
Study 30625189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (BCP + B. infantis)
Number of subjects: 8
Study 30625189 — intervention group
Group type: COMPARATOR
Intervention: BCP alone
Number of subjects: 8
Study 27837387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (≤3 doses of 100,000 IU)
Number of subjects: 50
Study 27837387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) with maintenance dose (3420 IU/day)
Number of subjects: 50
Study 27837387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (loading dose)
Number of subjects: 50
Study 26298226 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 126